A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma
Tóm tắt
Approximately 50% of uveal melanoma (UM) patients develop metastases preferentially in the liver leading to death within 15 months. Currently, there is no effective treatment for metastatic UM, in part because the tumor burden is typically high when liver metastases are detected through abnormal liver function tests (LFTs) or imaging studies. The use of LFTs results followed by diagnostic tests has high specificity and predictive values but low sensitivity, and better tests are needed for early diagnosis of the primary tumor as well as its metastatic spread. To evaluate serum biomarkers for the early detection of UM, multiplex immunoassays were developed. Magnetic bead-based multiplex immunoassays were developed for the selected serum biomarkers using a Bio-Plex 200 system. The dynamic ranges, lower limits of detection and quantification, cross-reactivity, and intra- and inter-assay precision were assessed. All proteins were analyzed in sera of 48 patients diagnosed with UM (14 metastatic, 9 disease–free (DF) ≥ 5 years, 25 unknown) and 36 healthy controls. The performance of the biomarkers was evaluated individually and in combination for their ability to detect UM. A 7-plex immunoassay of OPN, MIA, CEACAM-1, MIC-1, SPON1, POSTN and HSP27 was developed with negligible cross-reactivity, recovery of 84–105%, and intra-assay and inter-assay precision of 2.3–7.5% or 2.8–20.8%, respectively. Logistic regression identified a two-marker panel of HSP27 and OPN that significantly improved the individual biomarker performance in discriminating UM from healthy controls. The improved discrimination of a two-marker panel of MIA and MIC-1 was also observed between metastatic UM and DF, however not statistically significant due to the small sample size. The multiplex immunoassay provides sufficient analytical performance to evaluate serum biomarkers that complement each other in detection of UM, and warrants further validation with a larger number of patient samples.
Tài liệu tham khảo
Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 2012;32:1363–72.
Mooy CM, De Jong PT. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol. 1996;41:215–28.
Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973–1997. Ophthalmology. 2003;110:956–61.
Singh AD, Rennie IG, Kivela T, Seregard S, Grossniklaus H. The Zimmerman-McLean-Foster hypothesis: 25 years later. Br J Ophthalmol. 2004;88:962–7.
Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973–1997. Ophthalmology. 2003;110:962–5.
Damato B. Developments in the management of uveal melanoma. Clin Exp Ophthalmol. 2004;32:639–47.
Mudhar HS, Parsons MA, Sisley K, Rundle P, Singh A, Rennie IG. A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma. Histopathology. 2004;45:1–12.
Frenkel S, Nir I, Hendler K, Lotem M, Eid A, Jurim O, Pe’er J. Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol. 2009;93:1042–6.
Hendler K, Pe’er J, Kaiserman I, Baruch R, Kalickman I, Barak V, Frenkel S. Trends in liver function tests: a comparison with serum tumor markers in metastatic uveal melanoma (part 2). Anticancer Res. 2011;31:351–7.
Kaiserman I, Amer R, Pe’er J. Liver function tests in metastatic uveal melanoma. Am J Ophthalmol. 2004;137:236–43.
Francis JH, Patel SP, Gombos DS, Carvajal RD. Surveillance options for patients with uveal melanoma following definitive management. Am Soc Clin Oncol Educ Book. 2013;33:382–7.
Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Green DL, Hawkins BS, Hayman J, Jaiyesimi I, Kirkwood JM, Koh WJ, Robertson DM, Shaw JM, Thoma J. Collaborative Ocular Melanoma Study Group R. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol. 2004;22:2438–44.
Abildgaard SK, Vorum H. Proteomics of uveal melanoma: a minireview. J Oncol. 2013;2013:820953.
Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R, Pe’er J. Serum markers to detect metastatic uveal melanoma. Anticancer Res. 2007;27:1897–900.
Barak V, Frenkel S, Valyi-Nagy K, Leach L, Apushkin MA, Lin AY, Kalickman I, Baumann NA, Pe’er J, Maniotis AJ, Folberg R. Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker. Invest Ophthalmol Vis Sci. 2007;48:4399–402.
Barak V, Kaiserman I, Frenkel S, Hendler K, Kalickman I, Pe’er J. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1). Anticancer Res. 2011;31:345–9.
Haritoglou I, Wolf A, Maier T, Haritoglou C, Hein R, Schaller UC. Osteopontin and ‘melanoma inhibitory activity’: comparison of two serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica. 2009;223:239–43.
Kadkol SS, Lin AY, Barak V, Kalickman I, Leach L, Valyi-Nagy K, Majumdar D, Setty S, Maniotis AJ, Folberg R, Pe’er J. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci. 2006;47:802–6.
Klingenstein A, Haritoglou I, Schaumberger MM, Nentwich MM, Hein R, Schaller UC. Receiver operating characteristic analysis: calculation for the marker ‘melanoma inhibitory activity’ in metastatic uveal melanoma patients. Melanoma Res. 2011;21:352–6.
Missotten GS, Korse CM, van Dehn C, Linders TC, Keunen JE, Jager MJ, Bonfrer JM. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests. Tumour Biol. 2007;28:63–9.
Reiniger IW, Schaller UC, Haritoglou C, Hein R, Bosserhoff AK, Kampik A, Mueller AJ. “Melanoma inhibitory activity” (MIA): a promising serological tumour marker in metastatic uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2005;243:1161–6.
Schaller UC, Bosserhoff AK, Neubauer AS, Buettner R, Kampik A, Mueller AJ. Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res. 2002;12:593–9.
Suesskind D, Schatz A, Schnichels S, Coupland SE, Lake SL, Wissinger B, Bartz-Schmidt KU, Henke-Fahle S. GDF-15: a novel serum marker for metastases in uveal melanoma patients. Graefes Arch Clin Exp Ophthalmol. 2012;250:887–95.
Barisione G, Fabbi M, Gino A, Queirolo P, Orgiano L, Spano L, Picasso V, Pfeffer U, Mosci C, Jager MJ, Ferrini S, Gangemi R. Potential role of soluble c-Met as a new candidate biomarker of metastatic uveal melanoma. JAMA Ophthalmol. 2015;133:1013–21.
Chen LL, Tian JJ, Su L, Jing Y, Zhang SC, Zhang HX, Wang XQ, Zhu CB. DJ-1: a promising marker in metastatic uveal melanoma. J Cancer Res Clin Oncol. 2015;141:315–21.
Barak V, Pe’er J, Kalickman I, Frenkel S. VEGF as a biomarker for metastatic uveal melanoma in humans. Curr Eye Res. 2011;36:386–90.
Karagiannis P, Fittall M, Karagiannis SN. Evaluating biomarkers in melanoma. Front Oncol. 2014;4:383.
Ramasamy P, Murphy CC, Clynes M, Horgan N, Moriarty P, Tiernan D, Beatty S, Kennedy S, Meleady P. Proteomics in uveal melanoma. Exp Eye Res. 2014;118:1–12.
Sivan S, Suzan F, Rona O, Tamar H, Vivian B, Tamar P, Jacob S, Gal M, Michal L. Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients. Clin Dev Immunol. 2012;2012:290536.
Khatib N, Pe’er J, Ortenberg R, Schachter J, Frenkel S, Markel G, Amer R. Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers. Invest Ophthalmol Vis Sci. 2011;52:9368–72.
Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. Fibrogenesis Tissue Repair. 2012;5:7.
Coupland SE, Vorum H, Mandal N, Kalirai H, Honore B, Urbak SF, Lake SL, Dopierala J, Damato B. Proteomics of uveal melanomas suggests HSP-27 as a possible surrogate marker of chromosome 3 loss. Invest Ophthalmol Vis Sci. 2010;51:12–20.
Jmor F, Kalirai H, Taktak A, Damato B, Coupland SE. HSP-27 protein expression in uveal melanoma: correlation with predicted survival. Acta Ophthalmol. 2012;90:534–9.
Kudo Y, Siriwardena BS, Hatano H, Ogawa I, Takata T. Periostin: novel diagnostic and therapeutic target for cancer. Histol Histopathol. 2007;22:1167–74.
Kotobuki Y, Yang L, Serada S, Tanemura A, Yang F, Nomura S, Kudo A, Izuhara K, Murota H, Fujimoto M, Katayama I, Naka T. Periostin accelerates human malignant melanoma progression by modifying the melanoma microenvironment. Pigment Cell Melanoma Res. 2014;27:630–9.
Pyle-Chenault RA, Stolk JA, Molesh DA, Boyle-Harlan D, McNeill PD, Repasky EA, Jiang Z, Fanger GR, Xu J. VSGP/F-spondin: a new ovarian cancer marker. Tumour Biol. 2005;26:245–57.
Nambiar S, Mirmohammadsadegh A, Hassan M, Mota R, Marini A, Alaoui A, Tannapfel A, Hegemann JH, Hengge UR. Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance. Carcinogenesis. 2007;28:2501–10.
Fu Q, Zhu J, Van Eyk JE. Comparison of multiplex immunoassay platforms. Clin Chem. 2010;56:314–8.
Houser B. Bio-Rad’s Bio-Plex(R) suspension array system, xMAP technology overview. Arch Physiol Biochem. 2012;118:192–6.
Song J, Sokoll LJ, Pasay JJ, Rubin AL, Li H, Bach DM, Chan DW, Zhang Z. Identification of serum biomarker panels for the early detection of pancreatic cancer. Cancer Epidemiol Biomark Prev. 2019;28:174–82.
Griewank KG, Murali R. Pathology and genetics of uveal melanoma. Pathology. 2013;45:18–27.